Substance / Medication

Tazemetostat

Overview

Active Ingredient
tazemetostat
RxNorm CUI
2274378

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Bioavailability, Metabolism, and Excretion of [C]-Tazemetostat in Patients With B-Cell Lymphomas or Advanced Solid Tumors.
Chen Yingxue, Teng Renli, Ogier Julien · Clin Pharmacol Drug Dev · 2025
PMID: 39901520ObservationalFull text (PMC)
Elevated Bromide Levels Due to Tazemetostat Therapy Treated With Salt and Water Supplementation in Two Children With Atypical Teratoid Rhabdoid Tumor.
Galletta Thomas J, Benoit Stefanie W, Markham Justin et al. · Pediatr Blood Cancer · 2025
PMID: 40390194Case Report
Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma.
Tansir Ghazal, Rastogi Sameer, Shamim Shamim Ahmed et al. · Future Sci OA · 2021
PMID: 33815821Case ReportFull text (PMC)
A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System Events for Tazemetostat.
Liu Qiong, Luo Miaoqing, Gao Mengge et al. · Ther Innov Regul Sci · 2026
PMID: 40830697Other
Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy.
Hou Yingqin, Zak Jaroslav, Shi Yujie et al. · Cancer Immunol Res · 2025
PMID: 39365901PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tazemetostat (substance)
SNOMED CT
840405005
UMLS CUI
C4086895
RxNorm CUI
2274378

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.